Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16441025 | 0.86 | PRKCI (0.49) | PRKCICYP2A6KDM4CKDRCHRNA7 | |
| SCHEMBL30444309 | 0.81 | PRKCI (0.55) | PRKCICYP2A6TUBB4ATUBBTUBA3C | |
| SCHEMBL5080973 | 0.81 | PRKCI (0.55) | PRKCICYP2A6TUBB4ATUBBTUBA3C | |
| SCHEMBL7233306 | 0.79 | PRKCI (0.53) | PRKCICYP2A6KDM4CKDRCHRNA7 | |
| SCHEMBL18314120 | 0.79 | PRKCI (0.53) | PRKCICYP2A6KDM4CKDRCHRNA7 | |
| SCHEMBL8685783 | 0.78 | PRKCI (0.52) | PRKCICYP2A6KDM4CKDRCHRNA7 | |
| SCHEMBL4499757 | 0.77 | HTR2C (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL11009200 | 0.76 | MAPT (0.51) | PRKCICYP2A6KDRPPARDPPARA | |
| SCHEMBL26441685 | 0.76 | PRKCI (0.50) | PRKCICYP2A6KDM4CKDRCHRNA7 | |
| SCHEMBL5431673 | 0.75 | PRKCI (0.49) | PRKCICYP2A6KDM4CKDRCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855260-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC | 2015-08-27 | — | — | US | disclosed |
| US-9061998-B2 | Quinolinone derivatives | GLAXOSMITHKLINE LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130345212-A1 | QUINOLINONE DERIVATIVES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | disclosed |
| US-7700638-B2 | 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex | N. V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| WO-2010039186-A2 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | N.V. ORGANON (NL) | 2007-01-25 | — | — | US | disclosed |
| EP-1678144-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX | Akzo Nobel N.V. (NL) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040131-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | AKZO NOBEL N.V. (NL) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238480-A1 | QUINOLINONE DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | PRKCI 17/4885CYP2A6 2217/4885KDM4C 3702/4885 |
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | GABRB1, GABRA5, GABRB2 | PRKCI 1870/4885CYP2A6 611/4885KDM4C 2751/4885 |
| US-20130345212-A1 | QUINOLINONE DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | PRKCI 17/4885CYP2A6 2217/4885KDM4C 3702/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | PRKCI 3113/4885CYP2A6 107/4885KDM4C 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.